Effect of nateglinide on the size of LDL particles in patients with type 2 diabetes

Advances in Therapy

Volumn 23, Issue 4, 2006, Pages 549-555

  Onishi, Yutaka ^a   Fujisawa, Takashi ^a   Sakaguchi, Kazuhiko ^a   Maeda, Mitsuo ^a  

^a IHI CORPORATION   (Japan)

Author keywords

Insulin resistance; LDL particle size; Nateglinide; Postprandial hyperglycemia

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NATEGLINIDE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOREACTIVITY; INSULIN RESISTANCE; LIPOPROTEIN METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; STATISTICAL SIGNIFICANCE;

CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PARTICLE SIZE; PHENYLALANINE; TRIGLYCERIDES;

EID: 33750994907     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850044     Document Type: Article

References (24)

1. Koba S, Hirano T. Small dense low-density lipoprotein in Japanese men with coronary artery disease. Ann Intern Med. 2000;132:762.
2. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917-1921.
3. Yoshino G, Hirano T, Kazumi T. Treatment of small dense LDL. J Atheroscler Thromb. 2002; 9:266-275.
4. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
5. Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb. 1992;12: 1496-1502.
6. Hanefeld M, Fischer S, Julius U, et al. Risk factor for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11-year follow-up. Diabetologia. 1996;39: 1577-1583.
7. DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnosis criteria. Lancet. 1999;354:617-621.
8. DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnosis criteria. Arch Intern Med. 2000;167:397-405.
9. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
10. Tamasawa N, Matsui J, Ogawa Y, et al. Effect of doxazosin on the size of LDL particle in the type 2 diabetic patients with hypertension. J Diabetes Complications. 2000;14:135-139.
11. Miyashita Y, Iso Y, Hashiguchi S, et al. Effect of temocapril hydrochloride on serum lipid levels in patients with hypertensive type 2 diabetes mellitus. J Atheroscler Thromb. 2001;8:25-29.
12. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ. 1998;316:823-828.
13. Chu NV, Kong AP, Kim DD, et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care. 2002;25:542-549.
14. Austin MA, Edwards KL. Small dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Curr Opin Lipidol. 1996;7:167-171.
15. McLeod JF. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotrophic agent. Clin Pharmacokinet. 2004;43:97-120.
16. Shiba T. Improvement of insulin resistance by a new insulin secretagogue, nateglinide-analysis based on the homeostasis model. Diabetes Res Clin Pract. 2003;62:87-94.
17. Routolo G, Ericsson CG, Tettamanti C, et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezabibrate Coronary Atherosclerosis Intervention Trial (BACAIT). J Am Coll Cardiol. 1998;15:1648-1656.
18. Kazumi T, Kawaguchi A, Hozumi T, et al. Low density lipoprotein particle diameter in young, nonobese, normolipidemic Japanese men. Atherosclerosis. 1999;142:113-119.
19. Mine T, Miura K, Kitahara Y, Okano A, Kawamori R. Nateglinide suppresses postprandial hypertriglyceridemia in Zucker fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide. Biol Pharm Bull. 2002;25:1412-1416.
20. Vakkilainen J, Mero N, Schweizer A, Foley JE, Taskinen MR. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. Diabetes Metab Res Rev. 2002;18:484-490.
21. Saloranta C, Lahti K, Guitard C, et al. Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population. Diabetes Care. 2002;25:2141-2146.
22. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10-16.
23. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, for The STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet. 2002;359:2072-2077.
24. Mori Y, Kitahara Y, Miura K, Tajima N. Comparison of voglibose and nateglinide for their acute effects on insulin secretion and free fatty acid levels in OLETF rat portal blood after sucrose loading. Endocrine. 2004;23:39-43.